[Dextran for the prophylaxis of postoperative thromboembolism (author's transl)].
Dextran has a well-documented antithrombotic effect that is due to a reduction in platelet adhesions, increased lysability of thrombi, and improved blood flow. Anaphylactoid reactions may occur during the first 30--50 ccm of dextran infusion. They have an incidence of 1:80000 during anesthesia. The main advantage of dextran prophylaxis is the lack of bleeding complications. It is extremely effective in lowering the incidence of lethal pulmonary embolisms.
D000707:Anaphylaxis / Q000139:chemically induced; D001241:Aspirin / Q000627:therapeutic use; D003911:Dextrans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D011183:Postoperative Complications / Q000517:prevention & control*; D013923:Thromboembolism / Q000517:prevention & control*
D003911:Dextrans; D006493:Heparin; D001241:Aspirin
Medikamentöse Thrombose-Prophylaxe mit Dextran.